Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Brain mapping study aims to uncover why some epilepsy patients stop breathing during seizures

NCT ID NCT07599150

Knowledge-focused Sponsor: Hospices Civils de Lyon Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study will use brain electrodes (SEEG) and breathing monitors in 20 adults with drug-resistant epilepsy to map which brain areas control breathing during a challenge. The goal is to understand why some patients experience fatal breathing arrest after seizures (SUDEP). No treatment is tested—this is a knowledge-gathering study.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could reveal which brain regions are critical for breathing control during seizures, pointing toward future ways to predict or prevent SUDEP.
What could go wrong
This is a very early, small observational study (20 people) that only maps brain activity—it does not test any treatment. Results may not lead directly to clinical changes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 20 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Sep 2026

An estimate. Start dates often move.

Expected to finish

Oct 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 55 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Written informed consent obtained from study subject and ability for study subject to comply with the requirements of the study 2. Aged 18 to 55 years old 3. Diagnosis of drug-resistant focal epilepsy, as defined by the International League Against Epilepsy 20 4. Patients undergoing SEEG as part of presurgical evaluation 5. At least one SEEG electrode localized in the perisylvian cortex 6. At least one SEEG electrode localized in the premotor cortex Exclusion Criteria: 1\. Ongoing or chronic respiratory and/or cardiac insufficiency and/or ischemic cardiac disease 2. History of stroke in the last 5 years 3. Intracranial hypertension related to space-occupying lesion in the brain 4. Pregnant, parturient, or breastfeeding women 5. Individuals receiving psychiatric care 6. Individuals deprived of their liberty by judicial or administrative decision 7. Adults subject to legal protection measures (guardianship, curatorship) 8. Individuals not affiliated with a social security scheme or beneficiaries of a similar scheme \-

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Drug-resistant focal epilepsy are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

epilepsy focal epilepsy sudden arrhythmia death syndrome Sudden Unexpected Death in Epilepsy

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Epilepsy SUDEP

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Service de Neurologie Fonctionne et d'Epileptologie Hôpital Neurologique Pierre WERTHEIMER

    Bron, Rhone, 69500, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.